Critical Update to Cardiac Safety Assessments
Applied Clinical Trials
CDER official comments on the significance of ICH's new alternative path for identifying the cardiac safety issue of QT prolongation in non-cardiac drugs.
In December 2015, the ICH updated its E14 Guideline Q&A to define an alternative path for identifying the cardiac safety issue of QT prolongation in non-cardiac drugs. This is the most fundamental revision to the Q&A of “The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs” since its implementation in 2005.
This alternative path-call it “concentration effect modeling”-relies on intensive, high quality ECG analysis and the use of exposure response modeling to determine the extent of QTc prolongation. Proof of its validation is FDA’s acceptance of this approach in lieu of a TQT study earlier in 2015.
Applied Clinical Trials spoke with Norman Stockbridge, MD, PhD, Director of the Division of Cardiovascular and Renal Products in CDER’s Office of New Drugs, about this development. Stockbridge noted that it has always been a known that TQT studies are inefficient. He said, “It led to sponsors doing a separate study instead of piggybacking onto an existing study. Then because it was a special study, it was only conducted late in development. Also, the previous by-time-point analysis doesn’t use all the information; it just uses the information where the QT interval is the worst.”
However, getting to a new approach that also had an acceptable confidence level for the older TQT approach, took time In the end, Stockbridge says, FDA asked for a trial that formally compared the two approaches. The Cardiac Safety Research Consortium (CSRC) and IQPharma members initiated the IQ-CRSC study, of which the FDA was heavily involved in the design.
For more information, download the free report here.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
